NYSE MRK

Merck & Co., Inc.

Healthcare · Drug Manufacturers - General

Market cap$347.39B
P/E ratio111.75
Earnings / share1.26
Dividend yield2.34%
Beta0.22
Employees73,000

Company overview

Merck & Co., Inc. (MRK) at a glance

The week in numbers

$35B by 2028
Keytruda peak-sales target

Company expectation signals potential oncology demand before patent expiry.

Merck expects this Keytruda peak-sales level, according to comparative analysis.

Source report
9%
Gardasil sales decline

Reported decline reflects weaker demand across cited markets.

Comparative report says first-half Gardasil sales declined amid weaker demand.

Source report
$2.12 per share
Quarterly EPS estimate

Analyst estimate is reported as 17.8% below year ago.

Analysts forecast quarterly earnings, below the comparable prior-year period.

Source report
75%
Winrevair growth

Reported product growth may support newer-product diversification.

24/7 Wall St reports Winrevair growth in the previous quarter.

Source report
Sector
Healthcare
Headquarters
126 East Lincoln Avenue, Rahway, NJ 07065, United States
Chief executive
Robert M Davis
Employees
73,000
Founded
Jan 1, 1891
Exchange
NYSE
Industry
Drug Manufacturers - General
Country
United States
Trading currency
USD
Official website
merck.com
Company Overview
Read company overview

Merck & Co., Inc. is a healthcare company headquartered in Rahway, New Jersey, operating globally in human health and animal health. Led by Chief Executive Officer Robert M Davis, it employs 73,000 people. Outside the United States and Canada, the company conducts business under the Merck Sharp & Dohme, or MSD, name.

Its human health portfolio includes pharmaceuticals and vaccines for cancer, infectious disease, respiratory and cardiovascular conditions, sleep disorders, diabetes, and other medical needs. Brands include Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, Bridion, Prevymis, Winrevair, Ohtuvayre, Januvia and Janumet.

The company also supplies veterinary medicines, vaccines, and health-management offerings for livestock, aquaculture, and companion animals. Its animal health brands include Nuflor, Bovilis/Vista, Banamine, Safe-Guard, Bravecto, Sentinel, Nobivac, Caninsulin/Vetsulin, and Sure Petcare. Founded in 1891 as the American affiliate of the Merck Group, Merck & Co. remains a separate company.

Ownership & major shareholders

Merck & Co., Inc. shares trade on NYSE under MRK. A verified breakdown of major shareholders is not included in this profile.

The week in perspective

Weekly briefing

This week’s coverage presents Merck’s oncology franchise and newer launches as potential offsets to its Keytruda patent-expiry exposure, but the near-term backdrop is tempered by softer Gardasil demand and reduced earnings expectations. This is a coverage-based interpretation, not confirmation of operating improvement.

News balance

1 Risk signals4 Mixed

Positive signals

Positive signals include reported momentum in newer products: 24/7 Wall St cited quarter-on-quarter uptake for subcutaneous Keytruda Qlex and strong Winrevair growth, while the comparative report described Winrevair, Welireg and Capvaxive as meaningful contributors. Merck’s stated Keytruda peak-sales goal and broader launch plans could help diversify revenue if execution and clinical progress continue.

Risks to watch

Risks center on concentration and transition: the comparative report said Gardasil sales fell amid weaker demand and competition, while analysts’ upcoming-quarter forecasts imply lower earnings and slightly lower revenue. Keytruda’s expected loss of exclusivity remains a major dependency. One supplied item provides only a headline about divergent cancer-vaccine results, so its underlying evidence and implications cannot be assessed.

Developments worth following

Latest news

Company Review
Zacks

Pipeline diversification faces Gardasil and Keytruda pressures

A comparative analysis describes Keytruda as Merck’s central oncology driver, alongside contributions from newer products and Animal Health. It reports weaker Gardasil sales, especially in key markets, and notes Merck’s acquisitions and planned launches intended to broaden its portfolio.

If newer launches, pipeline programs and Animal Health expand as described, they could reduce reliance on Keytruda over time. Continued Gardasil weakness, competitive pressure and the approaching Keytruda exclusivity loss could make that transition more difficult.

Read source

Zacks

Analysts anticipate lower quarterly earnings and revenue

Analysts expect quarterly earnings of $2.12 per share and revenue of $17.23 billion, both below the prior-year period. The consensus earnings estimate was reduced over the preceding month, with projected product trends varying across Merck’s portfolio.

If these estimates prove accurate, the quarter would show pressure on reported earnings and revenue. Forecast growth in selected infectious-disease products may partly offset projected declines in Keytruda, alliance products and mature brands, but would not establish actual results.

Read source

24/7 Wall St.

New launches tested against Keytruda transition needs

24/7 Wall St reports that recent results included growth in Winrevair and subcutaneous Keytruda Qlex, while Keytruda declined modestly. It highlights early Lipfendra adoption, oncology pipeline execution and new-product traction as important indicators before Keytruda’s anticipated exclusivity loss.

Sustained uptake for Winrevair, Qlex and Lipfendra could support a smoother revenue transition if the reported trends persist. However, the report also notes repeated reductions in full-year EPS estimates and product-specific headwinds.

Read source

Investor's Business Daily

Headline flags uncertainty around cancer vaccine results

The supplied headline indicates that Merck and Moderna may have differing interpretations of cancer-vaccine results and questions whether the program remains viable. No article text or excerpt was supplied, so no clinical findings or company-specific conclusions are available.

If the headline reflects unresolved interpretation of trial evidence, the program’s contribution to Merck’s oncology pipeline could be uncertain. The absence of supporting text prevents assessment of trial design, results, safety, regulatory relevance or commercial impact.

Read source

Source report

Cash-flow thesis depends on oncology pipeline delivery

Simply Wall St says late-stage melanoma vaccine data and Keytruda-combination approvals may support longer-duration oncology cash flows. Its discussion also identifies development spending, manufacturing demands, profit-sharing arrangements and China-related policy risks as factors affecting projected cash generation.

If oncology programs translate into durable commercial products, projected cash-flow expansion could be supported. Those projections remain conditional on clinical, manufacturing, partnership and policy assumptions, rather than evidence of realized future cash flow.

Read source

(MRK) Merck & Co., Inc. Bundle

Get Full Bundle:
$17 $9
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5